ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

ישראל - עברית - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

ישראל - עברית - Ministry of Health

ferring pharmaceuticals ltd - somatropin - אבקה וממס להכנת תמיסה להזרקה - somatropin 4 mg/vial - somatropin - somatropin - short stature due to pituitary growth hormone deficiency turner's syndrome children suffering from renal insufficiency. children : short stature due to inadequate or failed secretion of pituitary growth hormone or turner's syndrome. short stature in children with renal insufficiency.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - cilazapril - טבליה - cilazapril 2.5 mg - cilazapril - cilazapril - treatment of essential hypertension, renal hypertension and chronic heart failure.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - cilazapril - טבליה - cilazapril 2.5 mg - cilazapril - cilazapril - treatment of essential hypertension, renal hypertension and chronic heart failure.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - cilazapril - טבליה - cilazapril 5 mg - cilazapril - cilazapril - treatment of essential hypertension, renal hypertension and chronic heart failure.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - cilazapril - טבליה - cilazapril 5 mg - cilazapril - cilazapril - treatment of essential hypertension, renal hypertension and chronic heart failure.

ישראל - עברית - Ministry of Health

teva israel ltd - cinacalcet as hydrochloride - טבליה - cinacalcet as hydrochloride 30 mg - cinacalcet

ישראל - עברית - Ministry of Health

rafa laboratories ltd - ramipril - קפסולות - ramipril 10 mg - ramipril - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.